Primary Biliary Cirrhosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Biliary Cirrhosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Primary Biliary Cirrhosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Primary Biliary Cirrhosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Biliary Cirrhosis Market.

The Primary Biliary Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Biliary Cirrhosis Pipeline Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Primary Biliary Cirrhosis treatment therapies with a considerable amount of success over the years.
• Primary Biliary Cirrhosis companies working in the treatment market are Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutica, Umecrine Cognition, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others, are developing therapies for the Primary Biliary Cirrhosis treatment
• Emerging Primary Biliary Cirrhosis therapies such as - PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Golexanolone, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others are expected to have a significant impact on the Primary Biliary Cirrhosis market in the coming years.
• In January 2023, A partnership and licence agreement between CymaBay Therapeutics, Inc. and Kaken Pharmaceutical Co., Ltd. has been announced in order to develop and market CymaBay's experimental medication seladelpar for the treatment of primary biliary cholangitis in Japan.According to the terms of the contract, Kaken has the sole right to create, promote, and sell seladelpar in Japan on behalf of PBC.
• In November 2022, Seladelpar findings in patients with primary biliary cholangitis (PBC) were presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC (November 4th-8th), according to CymaBay Therapeutics, Inc. Seladelpar treatment led to appreciable reductions in total cholesterol (TC), LDL-C, HDL-C, and triglycerides (TG), according to findings from a clinical poster presentation titled "Seladelpar Improved the Lipid Profile of Patients with Primary Biliary Cholangitis (PBC): Results from Phase 2 and 3 Clinical Studies".
• In April 2021, Seladelpar is being tested in a CymaBay Therapeutics placebo-controlled, randomised, Phase III research on patients with Primary Biliary Cholangitis (PBC) who have not responded well to or have an intolerance to the drug tosodeoxycholic acid (UDCA). The purpose of the trial is to compare the safety of seladelpar during a 12-month treatment period to a placebo and to assess the therapeutic impact of seladelpar on composite biochemical improvement in cholestasis indicators based on ALP and total bilirubin.
• In July 2021, CymaBay and Abingworth recently signed a development funding deal under which CymaBay would receive cash for seladelpar development expenditures up to $100 million, of which $75 million will be paid out in three installments over roughly six months. After enrollment in CymaBay's Phase III RESPONSE clinical study is complete, the company has the potential to obtain an additional $25 million in about two months

Primary Biliary Cirrhosis Overview
A chronic cholestatic liver disease of autoimmune origin known as primary biliary cirrhosis (PBC) is characterised by injury to the intrahepatic bile ducts, which may ultimately result in liver failure. 90% of those with the condition are women, and they are often in their fifth to seventh decades of life when they receive their diagnosis.

Get a Free Sample PDF Report to know more about Primary Biliary Cirrhosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Primary Biliary Cirrhosis Drugs Under Different Phases of Clinical Development Include:
• PVT-201: Parvus Therapeutics
• PDC-E2: Selecta Biosciences
• HPG-1860: Hepagene Therapeutics
• OP-724: Ohara Pharmaceutical
• CNP-104: Cour Pharmaceutica
• Golexanolone: Umecrine Cognition
• Volixibat: Mirum Pharmaceuticals
• Setanaxib: Calliditas Therapeutics
• ASC42: Gannex Pharma
• Norucholic acid: Dr Falk Pharma
• Elafibranor: Genfit
• Seladelpar: CymaBay Therapeutics

Route of Administration
Primary Biliary Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Primary Biliary Cirrhosis Pipeline Therapeutics Assessment
• Primary Biliary Cirrhosis Assessment by Product Type
• Primary Biliary Cirrhosis By Stage and Product Type
• Primary Biliary Cirrhosis Assessment by Route of Administration
• Primary Biliary Cirrhosis By Stage and Route of Administration
• Primary Biliary Cirrhosis Assessment by Molecule Type
• Primary Biliary Cirrhosis by Stage and Molecule Type

DelveInsight's Primary Biliary Cirrhosis Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Biliary Cirrhosis product details are provided in the report. Download the Primary Biliary Cirrhosis pipeline report to learn more about the emerging Primary Biliary Cirrhosis therapies at:
https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Primary Biliary Cirrhosis Therapeutics Market include:
Key companies developing therapies for Primary Biliary Cirrhosis are - Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals, and others.

Primary Biliary Cirrhosis Pipeline Analysis:
The Primary Biliary Cirrhosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Biliary Cirrhosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Biliary Cirrhosis Treatment.
• Primary Biliary Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Biliary Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Biliary Cirrhosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Biliary Cirrhosis drugs and therapies-
https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Biliary Cirrhosis Pipeline Market Drivers
• Increasing Cases of Primary Biliary Cirrhosis, increasing demand for effective treatment, increasing drug pipeline and FDA approval are some of the important factors that are fueling the Primary Biliary Cirrhosis Market.

Primary Biliary Cirrhosis Pipeline Market Barriers
• However, High cost of the treatment, challenging clinical trial study, lacking consensus stratification protocol to identify patients for secondline treatment and other factors are creating obstacles in the Primary Biliary Cirrhosis Market growth.

Scope of Primary Biliary Cirrhosis Pipeline Drug Insight
• Coverage: Global
• Key Primary Biliary Cirrhosis Companies: Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutica, Umecrine Cognition, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others
• Key Primary Biliary Cirrhosis Therapies: PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Golexanolone, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others
• Primary Biliary Cirrhosis Therapeutic Assessment: Primary Biliary Cirrhosis current marketed and Primary Biliary Cirrhosis emerging therapies
• Primary Biliary Cirrhosis Market Dynamics: Primary Biliary Cirrhosis market drivers and Primary Biliary Cirrhosis market barriers

Request for Sample PDF Report for Primary Biliary Cirrhosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Primary Biliary Cirrhosis Report Introduction
2 Primary Biliary Cirrhosis Executive Summary
3 Primary Biliary Cirrhosis Overview
4 Primary Biliary Cirrhosis- Analytical Perspective In-depth Commercial Assessment
5 Primary Biliary Cirrhosis Pipeline Therapeutics
6 Primary Biliary Cirrhosis Late Stage Products (Phase II/III)
7 Primary Biliary Cirrhosis Mid Stage Products (Phase II)
8 Primary Biliary Cirrhosis Early Stage Products (Phase I)
9 Primary Biliary Cirrhosis Preclinical Stage Products
10 Primary Biliary Cirrhosis Therapeutics Assessment
11 Primary Biliary Cirrhosis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Primary Biliary Cirrhosis Key Companies
14 Primary Biliary Cirrhosis Key Products
15 Primary Biliary Cirrhosis Unmet Needs
16 Primary Biliary Cirrhosis Market Drivers and Barriers
17 Primary Biliary Cirrhosis Future Perspectives and Conclusion
18 Primary Biliary Cirrhosis Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Primary Biliary Cirrhosis Market https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Biliary Cirrhosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Primary Biliary Cirrhosis Epidemiology https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Biliary Cirrhosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.